PRILENIA THERAPEUTICS DEV LTD has a total of 21 patent applications. It decreased the IP activity by 84.0%. Its first patent ever was published in 2014. It filed its patents most often in United States, Canada and Brazil. Its main competitors in its focus markets pharmaceuticals and biotechnology are SUTAAGEN KK, CENTRO DE INVESTIG Y DESARROLLO DE MEDICAMENTOS CIDEM and VERVA PHARMACEUTICALS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 5 | |
#2 | Canada | 4 | |
#3 | Brazil | 3 | |
#4 | Mexico | 3 | |
#5 | Israel | 2 | |
#6 | Chile | 1 | |
#7 | China | 1 | |
#8 | EPO (European Patent Office) | 1 | |
#9 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Hayden Michael | 9 |
#2 | Eyal Eli | 5 |
#3 | Michael Hayden | 5 |
#4 | Borowsky Beth | 4 |
#5 | Beth Borowsky | 4 |
#6 | Grachev Igor D | 4 |
#7 | Papapetropoulos Spyridon | 4 |
#8 | Eli Eyal | 4 |
#9 | Savola Juha-Matti | 4 |
#10 | Igor D Grachev | 4 |
Publication | Filing date | Title |
---|---|---|
CN109952100A | Puli more fixed for treating the purposes of anxiety and depression | |
CA3035099A1 | Use of pridopidine for treating dystonias |